Bisphosphonate therapy reduces the risk of fractures in women with postmenopausal osteoporosis, but the optimal duration of therapy is not known. In the randomized Fracture Intervention Trial Long-term Extension (FLEX) trial, investigators compared the effects on bone mineral density (BMD) of 5 years vs 10 years of alendronate therapy in a cohort of postmenopausal women. Black and colleagues Article report that women who discontinued alendronate at 5 years experienced moderate declines in BMD, although not to their pretreatment level, and a gradual increase in biochemical markers of bone turnover compared with women who continued therapy for 10 years. In exploratory analyses, the authors found that nonvertebral fracture risks were similar in both groups and clinically detected vertebral fractures were higher in women who discontinued therapy. In an editorial, Colón-Emeric Article discusses the implications of the FLEX trial results for women with osteoporosis.
Carandang and colleagues analyzed data from participants in the Framingham Study, original and offspring cohorts, who were free of prevalent stroke to assess temporal trends in stroke incidence, lifetime risk, severity, and 30-day mortality from 1950 through 2004. The authors found that stroke incidence decreased over time, but lifetime risk did not decline significantly. Stroke severity remained relatively stable, and 30-day mortality decreased significantly in men but not in women.
Proton pump inhibitor (PPI) therapy may affect bone through 2 opposing actions—reducing calcium absorption as a result of PPI-induced hypochlorhydria and reducing bone resorption through inhibition of osteoclastic vacuolar proton pumps. To investigate the net effect of PPI therapy on the risk of hip fracture, Yang and colleagues conducted a nested case-control study of patients who were 50 years and older and were users of PPI therapy or nonusers of acid suppressive therapy. The authors found a significantly increased risk of hip fracture among persons taking PPIs for more than 1 year. The risk of fracture increased with higher-dose therapy and longer duration of use.
Individuals who are prone to high-altitude pulmonary edema (HAPE) have exaggerated pulmonary hypertension and arterial hypoxemia at high altitude for reasons that are not clear. Limited evidence has suggested that a patent foramen ovale (PFO) might be a contributing factor. Allemann and colleagues investigated this possibility in a case-control study of HAPE-prone and HAPE-resistant mountaineers who underwent transesophageal echocardiography, Doppler echocardiography, and pulse oximetry at low and high altitude. The investigators found that the frequency of PFO was significantly higher in HAPE-prone than in HAPE-resistant persons. At high altitude, HAPE-prone individuals with a large PFO had more severe hypoxemia compared with persons having a small PFO or closed foramen ovale.
Grahic Jump Location
“When you name something, it's as it you give it life. My thyroid cancer was born on Monday, June 12.” From “A Bump in the Neck.”
Experts are trying to understand and reverse persistently increasing rates of preterm birth in the United States by promoting more research and by testing novel interventions.
End-of-life care for homeless patients is discussed in the case of Mr K, a 66-year-old man with metastatic renal cell carcinoma, who has been homeless for much of the past 50 years.
Authors may submit manuscripts for a JAMA theme issue on poverty and human development.
Join Dennis Black, PhD, January 17, 2007, from 2 to 3 PM eastern time to discuss the effects of continuing or stopping alendronate after 5 years. To register, go to http://www.ihi.org/AuthorintheRoom.
For your patients: Information about patent foramen ovale.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.